Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DGX Quest Diagnostics	$183.60 -0.4%	$175.09	$146.17 ▼ $185.26	$20.62B	0.46	988,648 shs	1.07 million shs
EXAS Exact Sciences	$46.68 -0.7%	$49.69	$38.81 ▼ $72.83	$8.90B	0.93	4.03 million shs	2.14 million shs
LH Labcorp	$276.51 -0.6%	$260.83	$209.38 ▼ $283.47	$23.11B	0.78	687,035 shs	384,680 shs
MYGN Myriad Genetics	$5.83 +5.4%	$5.13	$3.76 ▼ $29.30	$514.54M	1.89	2.48 million shs	988,315 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DGX Quest Diagnostics	+0.80%	+2.93%	+10.36%	+8.65%	+22.05%
EXAS Exact Sciences	+2.89%	+4.65%	-2.81%	-16.78%	-20.10%
LH Labcorp	+0.65%	+1.99%	+14.47%	+14.94%	+23.16%
MYGN Myriad Genetics	+0.36%	-5.79%	+24.27%	+40.71%	-79.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DGX Quest Diagnostics	4.4967 of 5 stars	1.3	2.0	4.2	4.7	2.8	2.5	2.5
EXAS Exact Sciences	4.9139 of 5 stars	4.5	5.0	0.0	4.7	3.7	2.5	0.6
LH Labcorp	4.6403 of 5 stars	2.3	5.0	2.5	4.2	2.9	2.5	1.3
MYGN Myriad Genetics	3.5592 of 5 stars	3.1	2.0	0.0	4.1	2.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DGX Quest Diagnostics	2.67	Moderate Buy	$186.00	1.31% Upside
EXAS Exact Sciences	2.92	Moderate Buy	$67.43	44.45% Upside
LH Labcorp	2.62	Moderate Buy	$289.58	4.73% Upside
MYGN Myriad Genetics	2.21	Hold	$12.45	113.63% Upside

Current Analyst Ratings Breakdown

Latest EXAS, LH, MYGN, and DGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	EXAS Exact Sciences	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $60.00
8/11/2025	EXAS Exact Sciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$70.00 ➝ $60.00
8/8/2025	EXAS Exact Sciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $64.00
8/7/2025	EXAS Exact Sciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	EXAS Exact Sciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$61.00 ➝ $53.00
8/7/2025	EXAS Exact Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$54.00 ➝ $46.00
8/7/2025	EXAS Exact Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/25/2025	LH Labcorp	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$282.00 ➝ $305.00
7/25/2025	LH Labcorp	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$290.00 ➝ $310.00
7/25/2025	LH Labcorp	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$285.00 ➝ $300.00
7/25/2025	LH Labcorp	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$283.00 ➝ $306.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DGX Quest Diagnostics	$9.87B	2.08	$13.45 per share	13.65	$64.97 per share	2.83
EXAS Exact Sciences	$2.76B	3.20	$5.59 per share	8.35	$13.04 per share	3.58
LH Labcorp	$13.48B	1.70	$22.28 per share	12.41	$101.96 per share	2.71
MYGN Myriad Genetics	$837.60M	0.65	$1.05 per share	5.53	$4.17 per share	1.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DGX Quest Diagnostics	$871M	$8.35	21.99	17.50	2.45	9.01%	15.24%	6.64%	10/28/2025 (Estimated)
EXAS Exact Sciences	-$1.03B	-$5.43	N/A	93.36	4.81	-34.19%	-1.75%	-0.76%	11/4/2025 (Estimated)
LH Labcorp	$746M	$9.06	30.52	15.76	1.78	5.66%	15.45%	7.02%	10/23/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$4.28	N/A	N/A	N/A	-47.45%	-5.17%	-3.44%	11/6/2025 (Estimated)

Latest EXAS, LH, MYGN, and DGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	EXAS Exact Sciences	-$0.02	$0.22	+$0.24	-$0.01	$774.43 million	$811.09 million
7/24/2025	Q2 2025	LH Labcorp	$4.14	$4.35	+$0.21	$2.84	$3.49 billion	$3.53 billion
7/22/2025	Q2 2025	DGX Quest Diagnostics	$2.57	$2.62	+$0.05	$2.47	$2.73 billion	$2.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DGX Quest Diagnostics	$3.20	1.74%	N/A	38.32%	14 Years
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
LH Labcorp	$2.88	1.04%	N/A	31.79%	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A

Latest EXAS, LH, MYGN, and DGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/13/2025	DGX Quest Diagnostics	quarterly	$0.80	1.79%	10/3/2025	10/3/2025	10/20/2025
7/10/2025	LH Labcorp	quarterly	$0.72	1.11%		8/28/2025	9/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DGX Quest Diagnostics	0.71	1.09	0.99
EXAS Exact Sciences	0.94	2.89	2.56
LH Labcorp	0.61	1.50	1.32
MYGN Myriad Genetics	N/A	1.42	1.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DGX Quest Diagnostics	88.06%
EXAS Exact Sciences	88.82%
LH Labcorp	95.94%
MYGN Myriad Genetics	99.02%

Insider Ownership

Company	Insider Ownership
DGX Quest Diagnostics	8.16%
EXAS Exact Sciences	1.20%
LH Labcorp	0.84%
MYGN Myriad Genetics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DGX Quest Diagnostics	56,000	111.82 million	102.70 million	Optionable
EXAS Exact Sciences	7,000	189.32 million	187.05 million	Optionable
LH Labcorp	70,000	83.10 million	82.40 million	Optionable
MYGN Myriad Genetics	2,700	93.04 million	90.81 million	Optionable

EXAS, LH, MYGN, and DGX Headlines

Recent News About These Companies

ANGLE plc partners with Myriad Genetics to advance cancer diagnostics

August 20 at 6:11 AM | msn.com

ANGLE (ANPCF) Partners with Myriad Genetics to Enhance Cancer Diagnostics

August 20 at 4:31 AM | gurufocus.com

ANGLE Announces Collaboration with Myriad Genetics | ANPCY Stock News

August 20 at 3:11 AM | gurufocus.com

ANGLE partners with Myriad Genetics on enhanced patient treatment approach in cancer

August 20 at 2:41 AM | proactiveinvestors.co.uk

Myriad Genetics reaffirms FY25 guidance

August 19 at 9:56 AM | msn.com

Myriad Genetics, Inc.: Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

August 18 at 10:45 AM | finanznachrichten.de

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer | MYGN Stock News

August 18 at 9:29 AM | gurufocus.com

Ben Wheeler Steps Up as CFO at Myriad Genetics (MYGN)

August 18 at 9:29 AM | gurufocus.com

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

August 18 at 9:29 AM | gurufocus.com

Myriad Genetics Appoints Ben R. Wheeler as CFO

August 18 at 9:05 AM | tipranks.com

Myriad Genetics announces CFO appointment

August 18 at 9:05 AM | seekingalpha.com

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

August 18 at 8:30 AM | globenewswire.com

Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by XTX Topco Ltd

August 15, 2025 | marketbeat.com

Myriad Genetics’s Q2 Earnings Call: Our Top 5 Analyst Questions

August 13, 2025 | finance.yahoo.com

MYGN Q2 Deep Dive: Oncology Strategy Shift and Product Execution Shape Guidance

August 13, 2025 | finance.yahoo.com

Myriad Genetics Reveals Insights from Cancer Risk Survey Highlighting Women's Attitudes Toward Health Screenings

August 13, 2025 | quiverquant.comQ

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

August 13, 2025 | globenewswire.com

Connor Clark & Lunn Investment Management Ltd. Buys 372,455 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

August 13, 2025 | marketbeat.com

Myriad Genetics’ Earnings Call: Growth Amid Challenges

August 13, 2025 | theglobeandmail.com

3 Reasons MYGN is Risky and 1 Stock to Buy Instead

August 13, 2025 | msn.com

Knott David M Jr Invests $1.42 Million in Myriad Genetics, Inc. (NASDAQ:MYGN)

August 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXAS, LH, MYGN, and DGX Company Descriptions

Quest Diagnostics NYSE:DGX

$183.60 -0.80 (-0.43%)

Closing price 03:59 PM Eastern

Extended Trading

$184.42 +0.82 (+0.45%)

As of 05:13 PM Eastern

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Exact Sciences NASDAQ:EXAS

$46.68 -0.32 (-0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$46.99 +0.31 (+0.66%)

As of 06:35 PM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Labcorp NYSE:LH

$276.51 -1.59 (-0.57%)

Closing price 03:59 PM Eastern

Extended Trading

$275.86 -0.65 (-0.23%)

As of 04:54 PM Eastern

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Myriad Genetics NASDAQ:MYGN

$5.83 +0.30 (+5.42%)

Closing price 04:00 PM Eastern

Extended Trading

$5.90 +0.07 (+1.18%)

As of 06:35 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time